- Direction
- Improving
- Own history
- 50th
- Peers
- 17th
- Persistence
- EMERGING
· Services-Medical Laboratories
RESEARCH SNAPSHOTLABCORP HOLDINGS INC.'s latest supported as-filed period reports revenue of $3.8B. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 153.59% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 3.98% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 14.80% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 6.92% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 14.13% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 29.08% · CORE
Level · gp.fundamentals.operating_margin
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents decreased 78.1%; Operating cash flow decreased 28.2%.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Inventory increased 10.6%; Inventory / revenue moved 66 bp higher.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Capital expenditure increased 68.9%; Capex / revenue moved 132 bp higher.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 5.8%; Operating margin moved 92 bp higher; Operating income increased 14.5%.
3 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 6.9%; Operating margin moved 58 bp lower; Operating income increased 1.4%.
3 evidence-backed componentsFree-cash-flow proxy changed -42.2% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
LH · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0000920148-26-000222SEC ↗8-KOct 28, 2026Period Oct 28, 20260000920148-26-000213SEC ↗8-KOct 21, 2026Period Oct 20, 20260000920148-26-000210SEC ↗8-KSep 30, 2026Period Sep 30, 20260000920148-26-000207SEC ↗8-KSep 22, 2026Period Sep 22, 20260000920148-26-000205SEC ↗8-KSep 10, 2026Period Sep 10, 20260000920148-26-000201SEC ↗4Sep 3, 2026Period Sep 1, 20260000920148-26-000193SEC ↗4Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 1, 2026Filed Sep 3, 2026 | Caveney Brian JEVP, Pres of BLS, CMO & CSO | Grant Or AwardDirect | 3,000 | $0 | $0 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Oyegunwa AkinboladeEVP, CIO & CTO | Grant Or AwardDirect | 750 | $0 | $0 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Vaughn Bryan TEVP and President, Diagnostics | Grant Or AwardDirect | 1,500 | $0 | $0 | Form 4 ↗ |
| Aug 17, 2026Filed Aug 18, 2026 | ANDERSON KERRII BDirector | Open Market SaleDirect | 3,000 | $318 | $954,060 | Form 4 ↗ |
| Aug 11, 2026Filed Aug 12, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 10.55% · CORE
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 0.81% · OPTIONAL
Operating cash flow changed -28.2% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Trade receivables changed +14.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Free-cash-flow proxy changed +47.0% from the comparable as-filed period.
Operating cash flow changed +45.6% from the comparable as-filed period.
Trade receivables changed +10.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Inventory changed +10.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-09-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0000920148-26-000192| Open Market SaleDirect |
| 4,669 |
| $320 |
| $1.5M |
| Form 4 ↗ |
| Aug 4, 2026Filed Aug 6, 2026 | Summy Amy B.EVP, Chief Marketing Officer | Open Market SaleDirect | 924 | $307 | $283,428 | Form 4 ↗ |
| Aug 3, 2026Filed Aug 5, 2026 | Wilkinson Peter JSVP, Chief Accounting Officer | Option ExerciseDirect | 1,338 | $0 | $0 | Form 4 ↗ |
| Aug 3, 2026Filed Aug 5, 2026 | Wilkinson Peter JSVP, Chief Accounting Officer | Option ExerciseDirect | 1,338 | $209 | $279,977 | Form 4 ↗ |
| Aug 3, 2026Filed Aug 5, 2026 | Wilkinson Peter JSVP, Chief Accounting Officer | Open Market SaleDirect | 1,338 | $309 | $413,751 | Form 4 ↗ |
| Aug 3, 2026Filed Aug 5, 2026 | Wilkinson Peter JSVP, Chief Accounting Officer | Open Market SaleDirect | 82 | $309 | $25,356 | Form 4 ↗ |
| Jul 2, 2026Filed Jul 6, 2026 | Vaughn Bryan TEVP and President, Diagnostics | Open Market SaleDirect | 234 | $286 | $66,968 | Form 4 ↗ |
| Jul 2, 2026Filed Jul 6, 2026 | Kyle Kathryn WEVP, Chief Legal Officer | Open Market SaleDirect | 92 | $286 | $26,329 | Form 4 ↗ |
| Jul 1, 2026Filed Jul 6, 2026 | Vaughn Bryan TEVP and President, Diagnostics | Tax WithholdingDirect | 93 | $284 | $26,401 | Form 4 ↗ |
| Jul 1, 2026Filed Jul 6, 2026 | Vaughn Bryan TEVP and President, Diagnostics | Option ExerciseDirect | 327 | $0 | $0 | Form 4 ↗ |
| Jul 1, 2026Filed Jul 6, 2026 | Kyle Kathryn WEVP, Chief Legal Officer | Option ExerciseDirect | 256 | $0 | $0 | Form 4 ↗ |
| Jul 1, 2026Filed Jul 6, 2026 | Vaughn Bryan TEVP and President, Diagnostics | Option ExerciseDirect | 327 | — | — | Form 4 ↗ |
| Jul 1, 2026Filed Jul 6, 2026 | Kyle Kathryn WEVP, Chief Legal Officer | Option ExerciseDirect | 256 | — | — | Form 4 ↗ |
| Jul 1, 2026Filed Jul 6, 2026 | Kyle Kathryn WEVP, Chief Legal Officer | Tax WithholdingDirect | 73 | $284 | $20,723 | Form 4 ↗ |
| Jun 8, 2026Filed Jun 10, 2026 | Kyle Kathryn WEVP, Chief Legal Officer | Open Market SaleDirect | 762 | $264 | $201,084 | Form 4 ↗ |
| May 11, 2026Filed May 13, 2026 | Schechter Adam HPresident & CEO | Open Market SaleDirect | 5,903 | $255 | $1.5M | Form 4 ↗ |